WHAT AND WHERE IS HEAVEN?

Does heaven exist? With well over 100,000 plus recorded and described spiritual experiences collected over 15 years, to base the answer on, science can now categorically say yes. Furthermore, you can see the evidence for free on the website allaboutheaven.org.

Available on Amazon
https://www.amazon.com/dp/B086J9VKZD
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)

VISIONS AND HALLUCINATIONS

This book, which covers Visions and hallucinations, explains what causes them and summarises how many hallucinations have been caused by each event or activity. It also provides specific help with questions people have asked us, such as ‘Is my medication giving me hallucinations?’.

Available on Amazon
https://www.amazon.com/dp/B088GP64MW 
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


Overload

Appetite suppressant

Category: Medicines

Type

Involuntary and voluntary

Introduction and description

 

As this entry is not a particularly happy one we have decided to contrast hell with heaven by using the photos of Katerina Plotnikova

An appetite suppressant is also known as an anorectic or anorexic (from the Greek an- = "without" and orexis = "appetite"), an anorexigenic or an  anorexiant.

Although in theory it includes 'dietary supplements', the idea that one should supplement a diet in order to lose weight or lose your appetite somehow does not ring true, but there are a number of pharmaceuticals on the market classified in this way. 

There are also, very alarmingly a number of over-the-counter 'slimming aids' which tend to be almost impossible to track, as they are here today and gone tomorrow, once their real contents have been identified by the drug control agencies.

 

As the pharmaceuticals are based on almost identical base drugs to those for obesity treatments, and their mechanism of action is also identical, the drugs in this class have been grouped with Obesity drugs.

The following list and comment comes from Wikipedia

The following drugs listed as "centrally-acting antiobesity preparations" in the Anatomical Therapeutic Chemical Classification System:

  • Phentermine
  • Diethylpropion
  • Rimonabant (cannabinoid antagonist selective for CB1. Withdrawn amidst concerns about psychiatric consequences of drug treatment)
  • Sibutramine (in some countries withdrawn from the market because of concerns regarding its cardiovascular effects)
  • Oxymetazoline (over-the-counter nasal decongestant)
 

The following are listed as appetite depressants by MeSH.

  • Benfluorex
  • Butenolide
  • Cathine
  • Diethylpropion
  • FG-7142
  • Phenmetrazine
  • Phentermine
  • Phenylpropanolamine
  • Pyroglutamyl-histidyl-glycine
  • Sibutramine

Other compounds with known appetite suppressant activity include:

  • Amphetamine (also known as amfetamine, US brand name of mixed amphetamine salts is Adderall)
  • Benzphetamine
  • Bupropion (Wellbutrin, formerly known as amfebutamone)—an atypical antidepressant
  • Bupropion/naltrexone (Contrave)
  • Dextroamphetamine (also known by its USAN)
  • Dexfenfluramine (the D-enantiomer of fenfluramine; withdrawn for the same reason as its racemate)
  • Dexmethylphenidate
  • Fenfluramine (one of the two components [the other being phentermine] of Fen-phen. Since discontinued to its potential for causing valvulopathies and pulmonary hypertension)
  • Glucagon
  • Methylenedioxypyrovalerone (MDPV)
  • Liraglutide (Saxenda)
  • Lorcaserin (Belviq)
  • Lisdexamfetamine dimesylate (Vyvanse)
  • Methamphetamine (also known as methamfetamine, US brand name Desoxyn)
  • Methylphenidate (Ritalin)
  • Phendimetrazine
  • Phentermine/topiramate (Qsymia)
  • Phenethylamine
  • Topiramate (Topamax—an anticonvulsant medication with weight loss side effect)

Where † indicates drugs that have been since withdrawn from the market because of adverse effects.

 

Epidemics of fatal pulmonary hypertension and heart valve damage associated with pharmaceutical anorectic agents have led to the withdrawal of products from the market.  This was the case with aminorex in the 1960s, and again in the 1990s with fenfluramine.

Likewise, association of the related appetite suppressant phenylpropanolamine with hemorrhagic stroke led the Food and Drug Administration (FDA) to request its withdrawal from the market in the United States in 2000, and similar concerns regarding ephedrine resulted in an FDA ban on its inclusion in dietary supplements, in 2004 (a Federal judge later overturned this ban in 2005 during a challenge by supplement maker Nutraceuticals).

It is also debatable as to whether the ephedrine ban had more to do with its use as a precursor in methamphetamine manufacture rather than legitimate health concerns.

Alternative treatments

Weight loss effects of water have been subject to some scientific research. Drinking water prior to each meal may help in appetite suppression. Consumption of 500 mL of water 30 minutes before meals has been correlated with modest weight loss (1–2 kg) in obese men and women.

 Please follow the link to Obesity drugs.

Related observations